Inherited determinants of ovarian cancer survival

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 995-1007

  Goode, Ellen L ^a   Maurer, Matthew J ^a   Sellers, Thomas A ^b   Phelan, Catherine M ^b   Kalli, Kimberly R ^a   Fridley, Brooke L ^a   Vierkant, Robert A ^a   Armasu, Sebastian M ^a   White, Kristin L ^a   Keeney, Gary L ^a   Cliby, William A ^a   Rider, David N ^a   Kelemen, Linda E ^c   Jones, Monica B ^a   Peethambaram, Prema P ^a   Lancaster, Johnathan M ^b   Olson, Janet E ^a   Schildkraut, Joellen M ^d   Cunningham, Julie M ^a   Hartmann, Lynn C ^a  

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Division of Population Health and Information   (Canada)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; FEMALE; GLYCOSYLATION; HAZARD RATIO; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 76049086838     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2553     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351: 2519-29.
3. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in smallvolume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
4. McGuire V, Jesser CA, Whittemore AS. Survival among U S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84: 399-403.
5. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7.
6. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007;82: 751-70.
7. Quaye L, Gayther SA, Ramus SJ, et al. The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 2008;14:5833-9.
8. Schultheis AM, Lurje G, Rhodes KE, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-63.
9. Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago PMH, California Phase II Consortia. Gynecol Oncol 2008;110:49-55.
10. Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci 2007;98:268-74.
11. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005;10:1881-96.
12. D'Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J 2008;2:7-12.
13. Chiantore MV, Vannucchi S, Mangino G, et al. Senescence and cell death pathways and their role in cancer therapeutic outcome. Curr Med Chem 2009;16:287-300.
14. Hajra KM, Tan L, Liu JR. Defective apoptosis underlies chemoresistance in ovarian cancer. Adv Exp Med Biol 2008;622:197-208.
15. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 2008;25:219-32.
16. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004;41:189-231.
17. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
18. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-81.
19. Sellers TA, Schildkraut JM, Pankratz VS, et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2536-43.
20. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006;16:1733-45.
21. Jones MB, Michener CM, Blanchette JO, et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 2003;9:44-51.
22. Chien J, Staub J, Avula R, et al. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 2005;24:5089-100.
23. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-61.
24. Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307:1072-9.
25. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 2004;429: 446-52.
26. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37:1217-23.
27. Olson JE, Ingle JN, Ma CX, et al. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2007;102:237-47.
28. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B 1972;34:187-220.
29. Habermann TM, Wang SS, Maurer MJ, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008;112:2694-702.
30. Wang SS, Maurer MJ, Morton LM, et al. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009;23: 596-602.
31. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:5439-46.
32. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007;31:383-95.
33. Taylor J, Tibshirani R. A tail strength measure for assessing the overall univariate significance in a dataset. Biostatistics 2006;7:167-81.
34. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
35. Fleming GF, Ronnett BM, Siedman J, Zaino RJ, Ruben SC. Epithelial Ovarian Cancer. In: Bakarat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology, 5th edition. Baltimore, Philadelphia: Lippincott Williams & Wilkins, 2009;763-835.
36. Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2005;15:710-26.
37. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Upregulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435-43.
38. Champion KJ, Guinea M, Dammai V, Hsu T. Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res 2008;68:4649-57.
39. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 2009;69:349-57.
40. Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J. Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int J Colorectal Dis 2009;24: 269-74.
41. Fogli A, Boespflug-Tanguy O. The large spectrum of eIF2B-related diseases. Biochem Soc Trans 2006;34:22-9.
42. Knutson KL, Krco C, Goodman K, et al. T cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24:4254-61.
43. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
44. Levina V, Nolen BM, Marrangoni AM, et al. Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res 2009;15:2647-56.
45. Lurje G, Hendifar AE, Schultheis AM, et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics 2009;19:95-102.
46. Lissoni P, Brivio F, Rovelli F, et al. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents 2000;14:275-7.
47. Bushley AW, Ferrell R, McDuffie K, et al. Polymorphisms of interleukin (IL)-1α, IL-1β, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 2004;95:672-9.
48. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol 2007;25:4513-5.